In CLL, TP53-aberrant subclones tend to expand in disease relapse frequently and have a crucial impact on CLL patients’ prognosis and survival as we reported previously [8, 47]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.